TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
FIVE FORCES ANALYSIS 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Substitutes 17
Rivalry 18
LEADING COMPANIES 19
Astra Zeneca 19
Novartis AG 23
Sanofi-Aventis Group 27
ThromboGenics 31
MARKET FORECASTS 33
Market value forecast 33
MACROECONOMIC INDICATORS 34
APPENDIX 36
Methodology 36
Industry associations 37
Related Datamonitor research 37
Disclaimer 38
ABOUT DATAMONITOR 39
Premium Reports 39
Summary Reports 39
Datamonitor consulting 39
LIST OF TABLES
Table 1: Belgium biotechnology market value: $ million, 2006–10 10
Table 2: Belgium biotechnology market segmentation I:% share, by value, 2010 11
Table 3: Belgium biotechnology market segmentation II: % share, by value, 2010 12
Table 4: Astra Zeneca: key facts 19
Table 5: Astra Zeneca: key financials ($) 21
Table 6: Astra Zeneca: key financial ratios 21
Table 7: Novartis AG: key facts 23
Table 8: Novartis AG: key financials ($) 24
Table 9: Novartis AG: key financial ratios 25
Table 10: Sanofi-Aventis Group: key facts 27
Table 11: Sanofi-Aventis Group: key financials ($) 28
Table 12: Sanofi-Aventis Group: key financials (€) 28
Table 13: Sanofi-Aventis Group: key financial ratios 29
Table 14: ThromboGenics: key facts 31
Table 15: Belgium biotechnology market value forecast: $ million, 2010–15 33
Table 16: Belgium size of population (million), 2006–10 34
Table 17: Belgium gdp (constant 2000 prices, $ billion), 2006–10 34
Table 18: Belgium gdp (current prices, $ billion), 2006–10 34
Table 19: Belgium inflation, 2006–10 35
Table 20: Belgium consumer price index (absolute), 2006–10 35
Table 21: Belgium exchange rate, 2006–10 35
LIST OF FIGURES
Figure 1: Belgium biotechnology market value: $ million, 2006–10 10
Figure 2: Belgium biotechnology market segmentation I:% share, by value, 2010 11
Figure 3: Belgium biotechnology market segmentation II: % share, by value, 2010 12
Figure 4: Forces driving competition in the biotechnology market in Belgium, 2010 13
Figure 5: Drivers of buyer power in the biotechnology market in Belgium, 2010 14
Figure 6: Drivers of supplier power in the biotechnology market in Belgium, 2010 15
Figure 7: Factors influencing the likelihood of new entrants in the biotechnology market in Belgium, 2010 16
Figure 8: Factors influencing the threat of substitutes in the biotechnology market in Belgium, 2010 17
Figure 9: Drivers of degree of rivalry in the biotechnology market in Belgium, 2010 18
Figure 10: Astra Zeneca: revenues & profitability 22
Figure 11: Astra Zeneca: assets & liabilities 22
Figure 12: Novartis AG: revenues & profitability 25
Figure 13: Novartis AG: assets & liabilities 26
Figure 14: Sanofi-Aventis Group: revenues & profitability 29
Figure 15: Sanofi-Aventis Group: assets & liabilities 30
Figure 16: Belgium biotechnology market value forecast: $ million, 2010–15 33
[Cerrar la tabla de contenidos]
